RTI Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Revance Therapeutics Inc

Watchlist Manager

Watchlist

Price: 3.44 EUR Market Closed

Market Cap: €997.8m

R	Revance Therapeutics Inc SWB:RTI	US
O	Om Infra Ltd BSE:531092	IN
E	Exponent Inc F:EP5	US
	Nine Entertainment Co Holdings Ltd ASX:NEC	AU

Profitability Summary

Revance Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

73%

Strong 3Y Average Gross Margin

68%

Gross Margin is Increasing

62% > 73%

Negative Operating Margin

-68%

Negative 3Y Average Operating Margin

-117%

Operating Margin is Increasing

-216% > -68%

Negative Net Margin

-75%

Negative 3Y Average Net Margin

-142%

Net Margin is Increasing

-225% > -75%

Negative Free Cash Flow Margin

-79%

Negative 3Y Average Free Cash Flow Margin

-94%

Free Cash Flow Margin is Increasing

-130% > -79%

Exceptional ROE

137%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-100%

ROIC is Increasing

-108% > -69%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.